Goldman Sachs Sticks to Its Buy Rating for AstraZeneca (AZN)
In a report released today, Rajan Sharma from Goldman Sachs maintained a Buy rating on AstraZeneca, with a price target of £163.89.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Sharma is a 3-star analyst with an average return of 3.0% and a 54.95% success rate. Sharma covers the Healthcare sector, focusing on stocks such as AstraZeneca, GlaxoSmithKline, and arGEN X.
In addition to Goldman Sachs, AstraZeneca also received a Buy from Berenberg Bank’s Luisa Hector in a report issued yesterday. However, on January 16, Deutsche Bank maintained a Sell rating on AstraZeneca (LSE: AZN).
Based on AstraZeneca’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of p15.19 billion and a net profit of p2.53 billion. In comparison, last year the company earned a revenue of p13.96 billion and had a net profit of p1.47 billion
Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AZN in relation to earlier this year.
Read More on GB:AZN:
Disclaimer & DisclosureReport an Issue
- AstraZeneca initiated with a Buy at Citi
- AstraZeneca to complete direct listing of shares on NYSE
- AstraZeneca Shifts US Listings to NYSE in Global Harmonisation Move
- EMA validates Type II Variation MAA for AstraZeneca, Daiichi’s Enhertu
- AstraZeneca price target raised to 11,000 GBp from 10,500 GBp at Deutsche Bank
